

DOR Natural Medicine Division Listening Session #10:

February 23, 2024 | 9:00 am - 12:00 pm

Join In-Person:

1707 Cole Blvd., Ste. 300 (Red Rocks Conference Room)
Lakewood, CO 80401

Join Zoom Meeting: <https://us02web.zoom.us/j/85402452433>

Meeting ID: 854 0245 2433

Agenda:

- I. Welcome Back
- II. Overview of Statutory Authority and Mandatory Rulemaking
- III. Recap of Prior Work and Updates
- IV. Open Discussion Topics
 - Licensing & Equity Considerations
 - Inventory Tracking
 - Packaging & Labeling
 - Previous Listening Sessions Follow-Up (*See additional resources for discussion topics and questions covered in previous sessions*).
- V. Next Steps

Discussion Guide & Questions:

The following questions are intended to guide initial discussions. Attendees are invited to raise additional questions or topics relevant to the Listening Session topic.

➤ **Licensing & Equity Considerations:**

- What kind of information should applicants be required to submit regarding financial interests?

- If the Department has the authority to limit the number of cultivation and manufacturing licenses issued, should it?
 - Is a tiered model for cultivation an appropriate strategy to proactively address concerns related to overproduction?
 - Are there any unique concerns or considerations to allowing a cultivation facility or manufacturing facility to co-locate with other license types (For example, occupational health and safety concerns).
 - **Occupational Licensing:** Should the Division consider incorporating any aspects of Oregon’s established framework for issuing worker permits? See [Rule 475A.480](#)
 - **Equity Considerations:** Should applicants for Natural Medicine Operation licenses be required to submit a Equity Impact Plan with initial and renewal applications? (For example: Outlining how the licensee will support equity and inclusion while avoiding commercialization and exploitation).
- **Inventory Tracking:**
- What inventory tracking mechanisms used by other industries could serve as a model for tracking regulated natural medicine?
 - At what point should regulated natural medicine be required to be tracked? (For example: from inoculation through administration vs. from harvest through administration).wq
 - How should the Division track any natural medicine that is ultimately not administered during an administration session? For example, how should licensees handle any natural medicine that is left after an administration session?
- **Regulated Natural Medicine Products Packaging & Labeling:**
- What information will be most critical for facilitators and participants to have access to on the label of regulated natural medicine and regulated natural medicine products?
 - What information would be critical for first responders or other emergency response professionals to have access to? Should this information also be on the label?

Additional Resources:

- [DOR Natural Medicine Division Website](#)
 - [2024 Rulemaking Schedule](#)
- Previous [Listening Session Materials, Recordings, and Summaries](#)
 - Agendas (with Discussion Topics):
 - [September 5, 2023](#) - SB 23-290 Overview & Introduction to the Natural Medicine Division
 - [September 12, 2023](#) - First Responder Training
 - [September 22, 2023](#) - Public Education Campaign
 - [September 27, 2023](#) - Testing Program Meeting
 - [October 3, 2023](#) - Cultivation & Manufacturing Practices
 - [November 13, 2023](#) - First Responder Training
 - [November 29, 2023](#) - Data Collection & Public Education Campaigns
 - [December 11, 2023](#) - Cultivation & Manufacturing Practices
 - [December 21, 2023](#) - Business Structures & Licensing Considerations
- [DORA Natural Medicine Health Act Website](#)